Alcon Acquired by Novartis
On December 15, 2010, Novartis (NYSE: NVS) agreed to acquire the remaining shares of Alcon, Inc. (NYSE: ACL) it doesn't currently own for $168 per share.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
View Older Stories View More Recent Stories
-
Radius Health Appoints Pharmaceutical Executive Jose Carmona as Chief Financial Officer
-
Dr. Stephen S. Lane joins Alcon as Chief Medical Officer and Global Head Franchise Clinical Strategy
-
Alcon announces EU launch of CyPass® Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma
-
Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued
-
UPDATE: Novartis (NVS) Said to Hire BofA for Alcon Business Review; Options Include Spinoff or Sale - Bloomberg
-
Jeffrey Peterson, M.D. first in Hawaii to use new glaucoma surgery device
-
Daily Report Honors Greenberg Traurig With Third Consecutive Litigation Department Of The Year Win
-
Beaver-Visitec International Names Shervin Korangy Chief Financial Officer and Chief Strategy Officer
-
Aerie Pharmaceuticals Announces Expansion of Commercialization Team
-
Glaukos shares risk steep decline as rivals pressure: Barron's
-
EU Adopts New Diagnostics and Medical Device Regulations, USDM Life Sciences Helps Organizations Comply
-
Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications
-
UPDATE: Cowen Downgrades Novartis (NVS) to Market Perform
-
Bench International Search Inc. Names Friederike Sommer Senior Vice President, Based In Zurich As Global Life Sciences Industry Undergoes Reinvention
-
Life Sciences Ontario Strengthens its Leadership with New Chair, Board Members
-
ChenMed Strategically Expands Executive Team
-
Alcon receives US FDA approval for new AcrySof® IQ ReSTOR® +2.5 Multifocal Toric IOL with ACTIVEFOCUS(TM) design for uncompromised distance vision and presbyopia correction
-
ThromboGenics Business Update - FY 2016
-
Barclays Starts Novartis (NVS) at Underweight
-
Exane BNP Paribas Downgrades Novartis (NVS) to Underperform
-
Caligor Enhances Operational and Commercial Leadership to Meet Growing Global Demand for Its Clinical Trial Supply Services
-
New Review of Optimal Dose and Cost-effectiveness of Ranibizumab Treatment of Diabetic Macular Oedema
-
Importance of Ocular, Systemic and Psychosocial Factors in the Management of the Diabetic Macular Oedema Patient with Antivascular Endothelial Growth Factor Therapy
-
Conatus Pharmaceuticals Promotes Daniel L. Ripley to Senior Vice President, Business Development, Program and Alliance Management
-
Alcon launches new trifocal toric intraocular lens for patients with astigmatism undergoing cataract surgery
-
Novartis (NVS) Posts Strong FY16 Results; Announces $5B Buyback, Reviewing Options for Alcon Division
-
Novartis delivered solid 2016 performance, with Growth Products[1] absorbing Gleevec US LOE; innovation momentum continued; announces share buyback
-
AZZ Inc. Appoints Ed McGough to the Board of Directors
-
Credit Suisse Downgrades Novartis (NVS) to Neutral
-
Novartis's (NVS) Alcon Gains FDA Approval for AcrySof IQ ReSTOR+3.0D Multifocal Toric IOL
-
Alcon receives US FDA approval for AcrySof® IQ ReSTOR® +3.0D Multifocal Toric intraocular lens for cataract patients
-
Novartis bolsters ophthalmology pipeline through acquisition of Encore Vision, Inc.
-
Aerie Pharmaceuticals Announces Appointment of Judith J. Robertson as Chief Commercial Officer
-
Novartis CEO plays down prospects for Actelion bid: Blick
-
Argentum and Alcon Settle Patent Dispute Over PAZEO®
-
Novartis backs off from 2016 date for testing Google autofocus lens
-
Alcon introduces new AIR OPTIX® plus HydraGlyde monthly replacement contact lenses at the American Academy of Optometry annual meeting
-
Newsom Eye Center Offers The Next Generation For LASIK In Central Florida With Contoura Vision
-
Adare Pharmaceuticals Appoints Dr. Peter Richardson as Vice President, Research & Development and Chief Medical Officer
-
Apartment List Series B
-
Sound Pharmaceuticals announces two new executive hires to accelerate its Meniere's drug development program
-
Acerus Announces Appointment of Tricia Symmes as Chief Operating Officer
-
Novartis (NVS) Tops Q3 EPS by 4c
-
Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
-
ThromboGenics Business Update - Q3 2016
-
Leanplum Raises $29M Series C Round Led By Canaan Partners; Expands Mobile Engagement Channels With Email
-
Alcon launches the CyPass® Micro-Stent at the American Academy of Ophthalmology (AAO) 2016 annual meeting
-
Fruit-Rich Mediterranean Diet with Antioxidants May Cut Age-Related Macular Degeneration Risk by More than a Third
-
Latest ThromboGenics' Clinical Data to be Presented at 2016 American Academy of Ophthalmology (AAO) Meeting in Chicago
-
Novaliq Strengthens Executive Management Team by Appointing Christian Roesky, PhD, as Chief Executive Officer

